{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:35:24Z","timestamp":1792784124641,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Charit\u00e9","id":[{"id":"https:\/\/ror.org\/001w7jn25","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>To provide a summary of the recent and expected developments related to the treatment of axial spondyloarthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>An increasing number of interleukin-17 blocking agents show efficacy in axial spondyloarthritis including both non-radiographic and radiographic forms. Janus kinase inhibitors showed promising results in phase II studies in radiographic axial spondyloarthritis and have, therefore, a potential to become a therapeutic option in this indication in the future. Inhibition of structural damage progression in axial spondyloarthritis seems to be possible in the case of effective and early anti-inflammatory treatment, although there are still open questions related to particular drug classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Despite major advances in the field and growing therapeutic options, there are still many open questions related to the optimized treatment strategies and to the individual choice of a drug in axial spondyloarthritis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11926-020-00924-5","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T11:03:55Z","timestamp":1595243035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Treatment of Axial Spondyloarthritis: What Does the Future Hold?"],"prefix":"10.1007","volume":"22","author":[{"given":"Denis","family":"Poddubnyy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"issue":"6","key":"924_CR1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383. https:\/\/doi.org\/10.1136\/ard.2009.108233.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"924_CR2","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/ard.2010.145995","volume":"70","author":"D Poddubnyy","year":"2011","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(8):1369\u201374. https:\/\/doi.org\/10.1136\/ard.2010.145995.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"924_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/art.37803","volume":"65","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D. Review: nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum. 2013;65(3):543\u201351. https:\/\/doi.org\/10.1002\/art.37803.","journal-title":"Arthritis Rheum"},{"issue":"10089","key":"924_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(16)31591-4.","journal-title":"Lancet."},{"issue":"6","key":"924_CR5","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"924_CR6","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285\u201399. https:\/\/doi.org\/10.1002\/acr.24025.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"924_CR7","first-page":"1805","volume":"33","author":"A Barkhuizen","year":"2006","unstructured":"Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol. 2006;33(9):1805\u201312.","journal-title":"J Rheumatol"},{"issue":"3","key":"924_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/ard.2007.075309","volume":"67","author":"J Sieper","year":"2008","unstructured":"Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis. 2008;67(3):323\u20139. https:\/\/doi.org\/10.1136\/ard.2007.075309.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"924_CR9","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/art.39690","volume":"68","author":"D Poddubnyy","year":"2016","unstructured":"Poddubnyy D, Listing J, Sieper J. Brief report: course of active inflammatory and fatty lesions in patients with early axial Spondyloarthritis treated with infliximab plus naproxen as compared to naproxen alone: results from the infliximab as first line therapy in patients with early active axial Spondyloarthritis trial. Arthritis Rheum. 2016;68(8):1899\u2013903. https:\/\/doi.org\/10.1002\/art.39690.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"924_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","volume":"73","author":"J Sieper","year":"2014","unstructured":"\u2022 Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014;73(1):101\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203201Important clinical trial targeting remission in very early axial spondyloarthritis.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"924_CR11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/annrheumdis-2018-213089","volume":"77","author":"M Dubreuil","year":"2018","unstructured":"Dubreuil M, Louie-Gao Q, Peloquin CE, Choi HK, Zhang Y, Neogi T. Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. Ann Rheum Dis. 2018;77(8):1137\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213089.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"924_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.7326\/M14-2470","volume":"163","author":"NN Haroon","year":"2015","unstructured":"Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients with Ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med. 2015;163(6):409\u201316. https:\/\/doi.org\/10.7326\/M14-2470.","journal-title":"Ann Intern Med"},{"issue":"11","key":"924_CR13","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1136\/ard.2011.151191","volume":"70","author":"G Bakland","year":"2011","unstructured":"Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70(11):1921\u20135. https:\/\/doi.org\/10.1136\/ard.2011.151191.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"924_CR14","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/art.23275","volume":"58","author":"IH Song","year":"2008","unstructured":"Song IH, Poddubnyy DA, Rudwaleit M, Sieper J. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2008;58(4):929\u201338. https:\/\/doi.org\/10.1002\/art.23275.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"924_CR15","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756\u201365.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"924_CR16","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75(8):1438\u201343. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207897.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"924_CR17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nrrheum.2016.42","volume":"12","author":"J Sieper","year":"2016","unstructured":"Sieper J, Poddubnyy D. New evidence on the management of spondyloarthritis. Nat Rev Rheumatol. 2016;12(5):282\u201395. https:\/\/doi.org\/10.1038\/nrrheum.2016.42.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"924_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/art.40866","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landewe R, et al. A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. Arthritis Rheum. 2019;71(7):1101\u201311. https:\/\/doi.org\/10.1002\/art.40866.","journal-title":"Arthritis Rheum"},{"issue":"26","key":"924_CR19","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1505066.","journal-title":"N Engl J Med"},{"issue":"10163","key":"924_CR20","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(18)31946-9.","journal-title":"Lancet."},{"issue":"10217","key":"924_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Ostergaard M, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(19)32971-X.","journal-title":"Lancet."},{"issue":"9","key":"924_CR22","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten D, Ostergaard M, Wei JC, Sieper J, Jarvinen P, Tam LS, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295\u2013302. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213328.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"924_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheum. 2019;71(2):258\u201370. https:\/\/doi.org\/10.1002\/art.40728.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"924_CR24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41584-019-0294-7","volume":"15","author":"J Sieper","year":"2019","unstructured":"\u2022 Sieper J, Poddubnyy D, Miossec P. The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol. 2019;15(12):747\u201357. https:\/\/doi.org\/10.1038\/s41584-019-0294-7Recent summary on the pathophysiological aspects of axial spondyloarthritis with a focus on IL-23 and IL-17 pathways.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"924_CR25","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"\u2022 van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210322The first study that showed clinical efficacy of a JAK-inhibitor in axial spondyloarthritis.","journal-title":"Ann Rheum Dis"},{"issue":"10162","key":"924_CR26","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2378\u201387. https:\/\/doi.org\/10.1016\/S0140-6736(18)32463-2.","journal-title":"Lancet."},{"issue":"10214","key":"924_CR27","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet. 2019;394(10214):2108\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(19)32534-6.","journal-title":"Lancet."},{"issue":"7","key":"924_CR28","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/rheumatology\/kex361","volume":"57","author":"D Poddubnyy","year":"2018","unstructured":"\u2022 Poddubnyy D, Sieper J. What is the best treatment target in axial spondyloarthritis: tumour necrosis factor alpha, interleukin 17, or both? Rheumatology (Oxford). 2018;57(7):1145\u201350. https:\/\/doi.org\/10.1093\/rheumatology\/kex361Discussion of a need and potential design of a strategy clinical trial in axial spondyloarthritis.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"924_CR29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","volume":"77","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Baraliakos X, Hermann KA, Landewe RBM, Machado PM, Maksymowych WP, et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis. 2018;77(5):699\u2013705. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212377.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"924_CR30","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/art.33465","volume":"64","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64(5):1388\u201398. https:\/\/doi.org\/10.1002\/art.33465.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"924_CR31","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","volume":"73","author":"S Ramiro","year":"2014","unstructured":"Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73(8):1455\u201361. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205178.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"924_CR32","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","volume":"75","author":"D Poddubnyy","year":"2016","unstructured":"Poddubnyy D, Protopopov M, Haibel H, Braun J, Rudwaleit M, Sieper J. High disease activity according to the ankylosing spondylitis disease activity score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis inception cohort. Ann Rheum Dis. 2016;75(12):2114\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209209.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"924_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","volume":"77","author":"C Molnar","year":"2018","unstructured":"Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2018;77(1):63\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211544.","journal-title":"Ann Rheum Dis"},{"key":"924_CR34","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2016","unstructured":"Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2016;76:1070\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209730.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"924_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13075-019-1911-1","volume":"21","author":"J Braun","year":"2019","unstructured":"Braun J, Haibel H, de Hooge M, Landewe R, Rudwaleit M, Fox T, et al. Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Arthritis Res Ther. 2019;21(1):142. https:\/\/doi.org\/10.1186\/s13075-019-1911-1.","journal-title":"Arthritis Res Ther"},{"key":"924_CR36","doi-asserted-by":"publisher","unstructured":"\u2022 Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2017. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211734The current version of treat-to-target recommendations for axial spondyloarthritis.","DOI":"10.1136\/annrheumdis-2017-211734"},{"issue":"6","key":"924_CR37","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63(6):665\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"924_CR38","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815\u201322. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201766.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"924_CR39","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/art.39257","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous Golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheum. 2015;67(10):2702\u201312. https:\/\/doi.org\/10.1002\/art.39257.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"924_CR40","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1186\/ar4464","volume":"16","author":"A Weiss","year":"2014","unstructured":"Weiss A, Song IH, Haibel H, Listing J, Sieper J. Good correlation between changes in objective and subjective signs of inflammation in short- but not long-diseased patients with axial spondyloarthritis treated with tumor necrosis factor-blockers. Arthritis Res Ther. 2014;16(1):R35. https:\/\/doi.org\/10.1186\/ar4464.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"924_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000749","volume":"4","author":"J Braun","year":"2018","unstructured":"Braun J, Deodhar A, Landewe R, Baraliakos X, Miceli-Richard C, Sieper J, et al. Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. RMD Open. 2018;4(2):e000749. https:\/\/doi.org\/10.1136\/rmdopen-2018-000749.","journal-title":"RMD Open"},{"issue":"9","key":"924_CR42","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/rheumatology\/kez090","volume":"58","author":"I Redeker","year":"2019","unstructured":"Redeker I, Callhoff J, Hoffmann F, Haibel H, Sieper J, Zink A, et al. Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Rheumatology (Oxford). 2019;58(9):1634\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kez090.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"924_CR43","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/annrheumdis-2012-201777","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, Srinivasan S, Zamani O, Mielants H, Choquette D, Pavelka K, et al. Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. Ann Rheum Dis. 2013;72(10):1621\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201777.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"924_CR44","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1136\/annrheumdis-2014-207151","volume":"74","author":"D Poddubnyy","year":"2015","unstructured":"Poddubnyy D, van Tubergen A, Landewe R, Sieper J, van der Heijde D. Assessment of SpondyloArthritis international S. development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. Ann Rheum Dis. 2015;74(8):1483\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2014-207151.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"924_CR45","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/art.40429","volume":"70","author":"U Weber","year":"2018","unstructured":"Weber U, Jurik AG, Zejden A, Larsen E, Jorgensen SH, Rufibach K, et al. Frequency and anatomic distribution of magnetic resonance imaging features in the sacroiliac joints of young athletes: exploring \u201cbackground noise\u201d toward a data-driven definition of sacroiliitis in early spondyloarthritis. Arthritis Rheum. 2018;70(5):736\u201345. https:\/\/doi.org\/10.1002\/art.40429.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"924_CR46","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1136\/annrheumdis-2018-213700","volume":"77","author":"RBM Landewe","year":"2018","unstructured":"Landewe RBM. Overdiagnosis and overtreatment in rheumatology: a little caution is in order. Ann Rheum Dis. 2018;77(10):1394\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213700.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"924_CR47","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/acr.22583","volume":"67","author":"R Aggarwal","year":"2015","unstructured":"Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015;67(7):891\u20137. https:\/\/doi.org\/10.1002\/acr.22583.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"924_CR48","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/art.20990","volume":"52","author":"M Rudwaleit","year":"2005","unstructured":"Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum. 2005;52(4):1000\u20138.","journal-title":"Arthritis Rheum"},{"key":"924_CR49","doi-asserted-by":"publisher","unstructured":"Poddubnyy D. Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis. Rheumatology (Oxford). 2020. https:\/\/doi.org\/10.1093\/rheumatology\/keaa250.","DOI":"10.1093\/rheumatology\/keaa250"},{"issue":"9","key":"924_CR50","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1002\/art.39208","volume":"67","author":"A Molto","year":"2015","unstructured":"Molto A, Granger B, Wendling D, Breban M, Dougados M, Gossec L. Brief report: nonsteroidal antiinflammatory drug-sparing effect of tumor necrosis factor inhibitors in early axial spondyloarthritis: results from the DESIR cohort. Arthritis Rheum. 2015;67(9):2363\u20138. https:\/\/doi.org\/10.1002\/art.39208.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"924_CR51","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/annrheumdis-2013-203460","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, et al. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST part 2. Ann Rheum Dis. 2014;73(1):108\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203460.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"924_CR52","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1136\/annrheumdis-2011-201010","volume":"71","author":"IH Song","year":"2012","unstructured":"Song IH, Althoff CE, Haibel H, Hermann KG, Poddubnyy D, Listing J, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis. 2012;71(7):1212\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201010.","journal-title":"Ann Rheum Dis"},{"issue":"10142","key":"924_CR53","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","volume":"392","author":"R Landewe","year":"2018","unstructured":"Landewe R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet. 2018;392(10142):134\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(18)31362-X.","journal-title":"Lancet."}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00924-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-020-00924-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00924-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T20:33:39Z","timestamp":1626726819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-020-00924-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1007\/s11926-020-00924-5","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]},"assertion":[{"value":"20 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Denis Poddubnyy has received grant\/research support from AbbVie, Lilly, MSD, Novartis, and Pfizer; has received consultation and\/or speaker fees from AbbVie, Biocad, BMS, Gilead, GSK, Lilly, MSD, Novartis, Pfizer, Samsung and UCB.Joachim Sieper has received consultation and\/or speaker fees from AbbVie, Boehringer Ingelheim, Janssen, Merk, Novartis, Pfizer, Roche, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"47"}}